Oxford Biomedica (OXB), a contract manufacturer specializing in cell and gene therapies, has signed a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO that operates the country’s first commercial viral‑vector manufacturing site. The agreement, which follows nonbinding terms reached in October 2025, grants VVMF a worldwide, nonexclusive license to OXB’s inAAVate manufacturing platform. VVMF also has an option to license OXB’s LentiVector techno...